The Triumph of Hope Over Science
By Mark Derr,
New York Times
| 02. 24. 2004
After I was diagnosed with Parkinson's disease two years ago,
at the relatively young age of 52, I read everything I could
about the condition's usual "progression" — an
odd word for degeneration. The worst-case prognosis is grim:
a long slide into physical and mental incapacity.
That is not going to happen to me, I said, as I began measuring
my physical decline. I am young enough that I may be able to
benefit from advances in medicine, especially in brain research.
Maybe with new medications I would be able to put off taking
L-dopa, the best drug for Parkinson's but one that loses its
effectiveness over time. Surely better treatments will become
available, I told myself.
So why didn't I welcome the news that researchers in South
Korea were able to clone a human embryo and extract viable stem
cells from it? After all, one of the researchers said their
goal was "not to clone humans, but to understand the causes
of diseases" — and one of the diseases named most
often was Parkinson's. Scientists say they may one...
Related Articles
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...